Bio News
Yungjin Pharm recorded an operating loss of 1.7 billion won in the first quarter of this year, swinging to a loss from a profit of 2.6 billion won in the same period a year earlier. Revenue during the period was 63.7 billion won, down 0.5% from a year earlier, while net loss was 2.2 billion won. The results are preliminary figures that have not been reviewed by an external auditor and may change during the finalization process.
BIOBOOK TEAM
biobookmedia@biobook.co.krMerck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
RDA develops technology to produce anti-inflammatory exosomes for pets and files patent application
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
